ARTICLE | Clinical News
Tavocept: Phase III started
January 25, 2010 8:00 AM UTC
BioNumerik Pharmaceuticals Inc., San Antonio, Texas Product: Tavocept ( BNP7787) Business: Cancer Molecular target: DNA Description: Water soluble cisplatin Indication: Treat advanced primary adenoca...